Unlocking The Potential of KIN17: A Protein with High Affinity for DNA and RNA

Target Name: KIN

NCBI ID: G22944

Content of Review Report on KIN Target / Biomarker

KIN

Unlocking The Potential of KIN17: A Protein with High Affinity for DNA and RNA

The KIN protein, also known as KIN17, is a protein that is expressed in many different tissues throughout the body. It is a member of the KIM (Kinesin-Light Chain) family, which is known for its role in the movement of cells and organelles. KIN17 is primarily localized to the endoplasmic reticulum (ER), where it is involved in the transport of various proteins, including pre- and post-translational modifications, to their final destination.

One of the unique features of KIN17 is its ability to bind to DNA and RNA with high affinity. This is the result of the protein's 17 amino acid residues, which contain a variety of different chemical groups that are able to interact with DNA and RNA. KIN17 has been shown to be highly effective at binding to DNA and RNA in a variety of cell types, including cultured neurons and breast cancer cells.

The binding of KIN17 to DNA and RNA is important for its role in the regulation of various cellular processes, including cell growth, apoptosis (programmed cell death), and gene expression. For example, KIN17 has been shown to play a role in the regulation of cell cycle progression, by binding to the protein p21 and preventing its phosphorylation and subsequent ubiquitination. This is important for the maintenance of the cell's growth checkpoint, which ensures that cell proliferation is limited to a controlled level.

In addition to its role in cell cycle regulation, KIN17 has also been shown to play a role in the regulation of apoptosis. This is the process by which cells undergo programmed cell death, which is a normal and important part of the cell's lifecycle. KIN17 has been shown to be involved in the regulation of apoptosis in various cell types, including neurons and cancer cells.

KIN17 has also been shown to play a role in the regulation of gene expression. This is the process by which cells use the information contained in their DNA to produce the proteins that are necessary for various cellular functions. KIN17 has been shown to interact with various transcription factors, including activator protein 1 (AP-1), which is a key factor in the regulation of cell growth and differentiation.

The potential clinical applications of KIN17 as a drug target or biomarker are vast. For example, KIN17 has been shown to be involved in the regulation of cell cycle progression, which could make it an attractive target for drugs that are designed to inhibit cell proliferation. Additionally, KIN17's ability to bind to DNA and RNA has led to its potential use as a biomarker for various diseases, including cancer.

In conclusion, the KIN protein is a unique and fascinating protein that has the potential to be a drug target or biomarker. Its ability to bind to DNA and RNA with high affinity, as well as its role in the regulation of cell cycle progression and apoptosis , make it an attractive target for small molecules and other therapeutic compounds. Further research is needed to fully understand the mechanisms of KIN17's behavior and its potential clinical applications.

Protein Name: Kin17 DNA And RNA Binding Protein

Functions: Involved in DNA replication and the cellular response to DNA damage. May participate in DNA replication factories and create a bridge between DNA replication and repair mediated by high molecular weight complexes. May play a role in illegitimate recombination and regulation of gene expression. May participate in mRNA processing. Binds, in vitro, to double-stranded DNA. Also shown to bind preferentially to curved DNA in vitro and in vivo (By similarity). Binds via its C-terminal domain to RNA in vitro

The "KIN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets